AQR Capital Management
HCAT icon

AQR Capital Management’s Health Catalyst HCAT Stock Holding History

AQR Capital Management’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$690K Buy
543,244
+458,307
+540% +$862K ﹤0.01% 2968
2025
Q4 		$203K Sell
84,937
-14,821
-15% -$40.5K ﹤0.01% 3354
2025
Q3 		$284K Sell
99,758
-15,256
-13% -$52.2K ﹤0.01% 3109
2025
Q2 		$434K Sell
115,014
-53,330
-32% -$210K ﹤0.01% 2693
2025
Q1 		$763K Buy
168,344
+149,981
+817% +$794K ﹤0.01% 2187
2024
Q4 		$130K Sell
18,363
-11,813
-39% -$94.1K ﹤0.01% 2738
2024
Q3 		$246K Sell
30,176
-58,152
-66% -$420K ﹤0.01% 2488
2024
Q2 		$564K Buy
+88,328
New +$567K ﹤0.01% 2004
2023
Q2 		– Sell
-26,324
Closed -$307K – 2226
2023
Q1 		$307K Sell
26,324
-91,712
-78% -$1.17M ﹤0.01% 1941
2022
Q4 		$1.25M Buy
118,036
+42,652
+57% +$412K ﹤0.01% 1473
2022
Q3 		$731K Buy
75,384
+52,043
+223% +$689K ﹤0.01% 1639
2022
Q2 		$338K Buy
+23,341
New +$398K ﹤0.01% 1818

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management's HCAT Position: Q1 2026 in Review

AQR Capital Management increased its Health Catalyst (HCAT) stake by 540% in Q1 2026, buying an estimated $862K and bringing the position to 543,244 shares worth $690K. The position accounts for ﹤0.01% of the portfolio, ranked #2968.

AQR Capital Management first reported a position in HCAT in Q2 2022 and has held it in 12 quarters since. The position peaked at $1.25M in Q4 2022. 130 funds tracked by Wall St. Rank hold HCAT as of Q1 2026.

  • AQR Capital Management held 543,244 shares of Health Catalyst worth $690K as of Q1 2026.
  • AQR Capital Management bought 458,307 Health Catalyst shares in Q1 2026, an estimated $862K.
  • Health Catalyst made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2968 holding.
  • AQR Capital Management first reported a position in Health Catalyst in Q2 2022 and has held it in 12 quarters since.
  • AQR Capital Management's Health Catalyst position peaked at $1.25M in Q4 2022.
  • 130 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.